DEDICATES BEIJING LAB
Newsom sees lab as keeping
San Francisco competitive in life sciences
November 28, 2005
SAN FRANCISCO -- (BUSINESS WIRE) -- Bridge Pharmaceuticals
yesterday dedicated its recently completed Bridge Zhongguancun
Preclinical Drug Development Laboratory I.
In attendance at the ceremony were: San Francisco Mayor Gavin
Newsom; Deputy Mayor Beijing Municipal Office Hao Lu; Beijing
Deputy Mayor Bo-Yuan Fan; US Embassy Senior Commercial Officer
Craig Allen; Former Beijing Deputy Mayor Zhao-Guang Hu; Director
of Beijing Municipal Industrial Development Bureau Lian-Yuan Cheng;
Director of Beijing Municipal Science Technology Office Hai Feng;
and Former San Francisco Mayor Frank Jordon.
This 7,800 square meter facility puts Bridge at the forefront
of preclinical outsourcing to China and will be the first and
only US level GLP and AAALAC designed facility in China. The Zhongguancun
facility will house primates, rodents, canines, rabbits. Services
will include: FDA compliant GLP toxicology, pharmacology, predictive
PK/ADMET, safety pharmacology, formulation and other services.
Through its Vital Bridge joint venture, Bridge has expert local
partners in China that provide animal supplies from the largest
and only US-franchised (Charles River and Marshall Farms) quality
animal breeding facilities in China.
For Bridge, the opening of this facility marks the next phase
in outsourcing preclinical drug development to Asia. By controlling
its own facility in China, Bridge will have the capacity and expertise
to provide FDA compliant preclinical drug development services
to pharmaceutical and biotech companies throughout the world.
This new facility positions Bridge as the leading preclinical
CRO in China targeting US and EU biopharmaceutical companies.
"The San Francisco Bay Area is the birthplace of biotech
and has remained the worldwide leader in life sciences innovation.
Escalation of the price of drugs, as evidenced by California's
recent ballot initiative, is an increasing hardship and concern,"
said San Francisco Mayor Gavin Newsom.
"By combining the technical resources and innovation of
both the San Francisco Bay Area and Beijing's life sciences community,
this state-of-the-art facility represents the next wave of global
cooperation and evolution of life sciences development. Bridge,
and companies like Bridge, will allow San Francisco to remain
competitive in the life sciences, and cost effectively develop
more drugs, for smaller markets, in the new era of personalized
molecular medicine. We are pleased to see that a Bay Area company,
Bridge Pharmaceuticals, is taking the lead in this exciting global
evolution of the very best of the east and west."
Founded in 2004, Bridge Pharmaceuticals, Inc. was spun-out of
SRI International (formerly Stanford Research Institute) to develop
preclinical service and drug development capabilities through
leverage of the Asian market. To date, Bridge has been subcontracting
work through laboratories in China and Taiwan (Beijing, Shanghai,
Chengdu, Taipei and elsewhere).
Bridge is the first company to successfully use all China preclinical
and CMC data for successful filing of IND's with the US FDA and
did so twice this year.
"Two years ago, we asked a simple question -- why can't
one perform FDA compliant drug development in China for US clients
at a fraction of the normal price?" CEO and President, Glenn
Rice, Ph.D. said.
"China has the world's leading primate animal supply, highly
qualified technical staff, good English language skills and excellent
worker productivity, in addition to significant cost savings.
Bridge builds on China's strengths by adding: SOP sourcing from
the US, world class facilities in the leading life sciences park
in China, FDA compliance, AAALAC level animal welfare, real time
data monitoring, combined with a US headquartered company that
envisions flexible partnerships.
"Of course doing business in China takes a lot of local
know how, experienced investment strategy and government support.
We are combining the best of east and west and we are confident
it is going to revolutionize preclinical drug development worldwide.
We are indebted to our investors, particularly Peter Liu, Chairman
of the WI Harper Group who has guided our business from day one
About Bridge Pharmaceuticals
Bridge Pharmaceuticals is a US-headquartered, SRI International
spin-off company focused on providing cost effective, FDA compliant
drug development services in Asia for US, EU and Asian based clients.
Bridge has also formed BridgeNet, an unprecedented network of
pre-screened chemical and manufacturing service providers in China
and Taiwan, which provides western clients with a single point
of contact to access highly qualified and cost effective drug
development services in Asia. Bridge provides complete end-to-end
drug development expertise including US IND submissions. Bridge
focuses its development work in Taiwan and China.
For more information, visit www.BridgePharmaceuticals.com
or call 650-859-3853.